EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Recurrence Dynamics of Pathological N2 Non–Small Cell Lung Cancer Based on IASLC Residual Tumor Descriptor

In Ha Kim, Geun Dong Lee, Sehoon Choi, Hyeong Ryul Kim, Yong-Hee Kim, Dong Kwan Kim, Seung-Il Park, Jae Kwang Yun

Cancer Research and Treatment · 2025

DOI: 10.4143/crt.2024.150 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Research and Treatment, 2025. Verfasst von In Ha Kim und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, Ulsan University College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Recurrence, Local, Neoplasm, Residual. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PurposeThis study investigated the recurrence patterns and timing in patients with pathologic N2 (pN2) non-small cell lung cancer (NSCLC) according to the residual tumor (R) descriptor proposed by the International Association for the Study of Lung Cancer (IASLC).Materials and MethodsFrom 2004 to 2021, patients with pN2 NSCLC who underwent anatomical resection were analyzed according to the IASLC R criteria using medical records from a single center. Survival analysis was performed using Cox proportional hazards models. Recurrence patterns between complete (R0) and uncertain resections (R[un]) were compared.ResultsIn total, 1,373 patients were enrolled in this study: 576 (42.0%) in R0, 286 (20.8%) in R(un), and 511 (37.2%) in R1/R2 according to the IASLC R criteria. The most common reason for R(un) classification was positivity for the highest lymph node (88.8%). In multivariable analysis, the hazard ratios for recurrence in R(un) and R1/R2 compared to R0 were 1.18 (95% confidence interval [CI], 0.96–1.46) and 1.58 (1.31–1.90), respectively. The hazard rate curves displayed similar patterns among groups, peaking at approximately 12 months after surgery. There was a significant difference in distant recurrence patterns between R0 and R(un). Further analysis after stratification with the IASLC N2 descriptor showed significant differences in distant recurrence patterns between R0 and R(un) in patients pN2a1 and pN2a2 disease, but not in those with pN2b disease.ConclusionThe IASLC R criteria has prognostic relevance in patients with pN2 NSCLC. R(un) is a highly heterogeneous group, and the involvement of the highest mediastinal lymph node can affect distant recurrence patterns.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsNeoplasm Recurrence, LocalNeoplasm, ResidualHumansFemaleMaleMiddle AgedAgedRetrospective StudiesAdultNeoplasm StagingPrognosisPneumonectomyAged, 80 and over

Stichwörter der Autor:innen

Lung neoplasmsN2RecurrenceResidual tumor

Autor:innen und Institutionen

  • Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, Ulsan University College of Medicine, Seoul, Korea.

Zitieren

APA

Kim, I. H., Lee, G. D., Choi, S., Kim, H. R., Kim, Y. H., Kim, D. K., Park, S. I., & Yun, J. K. (2025). Recurrence Dynamics of Pathological N2 Non–Small Cell Lung Cancer Based on IASLC Residual Tumor Descriptor. Cancer Research and Treatment. https://doi.org/10.4143/crt.2024.150

Vancouver

Kim IH, Lee GD, Choi S, Kim HR, Kim YH, Kim DK, et al. Recurrence Dynamics of Pathological N2 Non–Small Cell Lung Cancer Based on IASLC Residual Tumor Descriptor. Cancer Research and Treatment. 2025. doi:10.4143/crt.2024.150

BibTeX
@article{Kim2025,
  author = {Kim, In Ha and Lee, Geun Dong and Choi, Sehoon and Kim, Hyeong Ryul and Kim, Yong-Hee and Kim, Dong Kwan and Park, Seung-Il and Yun, Jae Kwang},
  title = {Recurrence Dynamics of Pathological N2 Non–Small Cell Lung Cancer Based on IASLC Residual Tumor Descriptor},
  journal = {Cancer Research and Treatment},
  year = {2025},
  doi = {10.4143/crt.2024.150}
}
Kostenlos starten →